| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4290ba3f2027c29ecbc854244baf93a8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b7cb6a38dbfd3a4b2dfd65329dd0461d |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 |
| filingDate |
2009-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2010-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2cbfaa7eac6e0612e663f0838bcf0acd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f288a4b667bc8cc56829c122d0c11703
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc0f5d52632441e59b7adb6bc34c02e1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b9d451934fd0ac2f7fe14d4cd601af3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17f61346553a24c6a388cd39a1051a25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4eb4bd83e9a4310ceb02d4badca18ffe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a8ee9220f4008c0784d6bdb5bab5c2d7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6f5978620baaee0828bcc5c12939767
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a98abadaf20a507bdd2d814cd4f9d59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_edca3617939004f23c15b47e96bc15b5 |
| publicationDate |
2010-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2401307-C1 |
| titleOfInvention |
RECOMBINANT PLASMID DNA pFK2 PROVIDING SYNTHESIS OF RECOMBINANT PEPTIDE BEING HUMAN KAPPA CASEIN FRAGMENT ANALOGUE, METHOD FOR PREPARING RECOMBINANT PEPTIDE, AND RECOMBINANT PEPTIDE, HUMAN KAPPA CASEIN FRAGMENT ANALOGUE EXHIBITING APOPTOTIC ACTIVITY IN RELATION TO MALIGNANT CELLS |
| abstract |
FIELD: medicine. ^ SUBSTANCE: invention can be used in medical and biologic industry for preparing antineoplastic drugs. Plasmid DNA pFK2 providing synthesis of recombinant analogue of human kappa casein fragment, in Escherichia coli cells is designed; and a method for preparing a recombinant product with using it is described. The recombinant analogue of human kappa-casein fragment recovered from Escherichia coli cells transformed by recombinant plasmid DNA pFK2 has molecular weight of approximately 16 kDa; consists of residual methionine, human kappa-casein fragment with 24 on 134 amino acid residue and C-terminal histidine path and exhibits apoptotic activity in relation to malignant cells. ^ EFFECT: higher anticancer activity of the compounds. ^ 3 cl, 6 dwg, 4 ex |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2683221-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-023387-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2693251-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2619050-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2461566-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2619053-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2495126-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-023475-B1 |
| priorityDate |
2009-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |